ストックスクリーナーアプリを入手
12.38
0.96%
-0.12
アフターアワーズ：
12.38
前日終値:
$12.50
開ける：
$12.5
24時間の取引高:
1.93M
Relative Volume:
0.68
時価総額：
$1.76B
収益：
-
当期純損益:
$-294.51M
株価収益率:
-3.4775
EPS:
-3.56
ネットキャッシュフロー:
$-244.42M
1週間 パフォーマンス:
+10.93%
1か月 パフォーマンス:
+49.52%
6か月 パフォーマンス:
-11.00%
1年 パフォーマンス:
-72.93%
1日の値動き範囲:
$12.19
$12.68
1週間の範囲:
$10.78
$12.68
52週間の値動き範囲:
$6.36
$47.45
Dyne Therapeutics Inc Stock (DYN) Company Profile
DYN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
12.38 | 1.78B | 0 | -294.51M | -244.42M | -3.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-24 | 開始されました | Bernstein | Mkt Perform |
| 2025-06-11 | 再開されました | Raymond James | Outperform |
| 2025-06-02 | 再開されました | Oppenheimer | Outperform |
| 2025-05-29 | 開始されました | Evercore ISI | Outperform |
| 2025-03-12 | 開始されました | BMO Capital Markets | Outperform |
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2024-12-13 | 開始されました | Robert W. Baird | Outperform |
| 2024-11-26 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-10-24 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-05-21 | 繰り返されました | Chardan Capital Markets | Buy |
| 2024-04-30 | 開始されました | Morgan Stanley | Overweight |
| 2024-02-20 | 開始されました | H.C. Wainwright | Buy |
| 2023-02-27 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2023-02-15 | 開始されました | Oppenheimer | Outperform |
| 2023-01-26 | 開始されました | Guggenheim | Buy |
| 2022-07-20 | 開始されました | Chardan Capital Markets | Buy |
| 2022-07-12 | 開始されました | Raymond James | Outperform |
| 2020-10-12 | 開始されました | JP Morgan | Overweight |
| 2020-10-12 | 開始されました | Jefferies | Buy |
| 2020-10-12 | 開始されました | Piper Sandler | Overweight |
| 2020-10-12 | 開始されました | Stifel | Buy |
すべてを表示
Dyne Therapeutics Inc (DYN) 最新ニュース
Dyne Therapeutics Advances DMD Treatment with DYNE-251 Study - MSN
Short Interest Drops in Dyne Therapeutics Inc. After RallyJuly 2025 Setups & High Return Stock Watch Alerts - sundaytimes.kr
Dyne Therapeutics Inc. Shows Risk Reward Favoring UpsideLow Capital High Return Stock Plans Reviewed - 선데이타임즈
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc.DYN - WV News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN - GlobeNewswire Inc.
Dyne Therapeutics Trading Resumes - AInvest
Is Dyne Therapeutics Reaching New Heights? - StocksToTrade
Dyne Therapeutics price target lowered to $13 from $34 at Oppenheimer - TipRanks
Oppenheimer Lowers Dyne Therapeutics (DYN) Price Target to $13.00 | DYN Stock News - GuruFocus
Oppenheimer Lowers Dyne Therapeutics (DYN) Price Target to $13.0 - GuruFocus
Dyne Therapeutics (DYN) Earns Breakthrough Therapy Status for DY - GuruFocus
Dyne Therapeutics Shares Rise 3.6% After FDA Grants Breakthrough Therapy Status - MSN
Dyne Reports Wider Loss in Fiscal Q2 - AOL.com
Dyne Therapeutics stock gains as DYNE-251 receives FDA breakthrough designation - Investing.com Canada
Dyne Therapeutics (DYN) Gains FDA Breakthrough Status for DYNE-2 - GuruFocus
Dyne Therapeutics stock rises after FDA grants breakthrough therapy status By Investing.com - Investing.com Australia
Dyne Therapeutics stock rises after FDA grants breakthrough therapy status - Investing.com
Dyne gets FDA breakthrough therapy status for DMD therapy - Seeking Alpha
Dyne Therapeutics (DYN) Earns Breakthrough Therapy Status for DYNE-251 - GuruFocus
Dyne Therapeutics Gains FDA Breakthrough Designation for DYNE-251 - TipRanks
Dyne Therapeutics Announces Breakthrough Therapy Designation For DYNE-251 - Nasdaq
Dyne Therapeutics Announces FDA Breakthrough Therapy Designation - GuruFocus
Dyne Therapeutics Announces FDA Breakthrough Therapy Designation For Dyne-251 In Duchenne Muscular Dystrophy - TradingView
Dyne Therapeutics Receives FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy - Quiver Quantitative
Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD) - The Manila Times
Dyne Therapeutics Announces FDA Breakthrough Therapy - GlobeNewswire
FDA Breakthrough: DYNE-251 DMD Drug Could Transform Treatment by 2026 - Stock Titan
What makes Dyne Therapeutics Inc. stock price move sharplyAchieve breakthrough profits with expert advice - Jammu Links News
What is Dyne Therapeutics Inc. company’s growth strategyTremendous growth opportunities - Jammu Links News
Is it the right time to buy Dyne Therapeutics Inc. stockMarket-beating returns - Jammu Links News
Why is Dyne Therapeutics Inc. stock attracting strong analyst attentionAchieve breakthrough gains with expert advice - Jammu Links News
Should I hold or sell Dyne Therapeutics Inc. stock in 2025Build wealth steadily with proven investment techniques - Jammu Links News
What is the risk reward ratio of investing in Dyne Therapeutics Inc. stockAchieve breakthrough investment performance - Jammu Links News
How many analysts rate Dyne Therapeutics Inc. as a “Buy”Unlock powerful market insights for success - jammulinksnews.com
Does Dyne Therapeutics (DYN) Have the Potential to Rally 285.57% as Wall Street Analysts Expect? - MSN
Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights - ADVFN Brasil
Pomerantz Investigates Dyne Therapeutics for Securities Fraud. - AInvest
Stifel Downgrades Dyne Therapeutics to Buy, Lowers PT to $36. - AInvest
Stifel lowers Dyne Therapeutics stock price target to $36 on endpoint changes - Investing.com Canada
Dyne Therapeutics (DYN) Gets a Buy from Scotiabank - The Globe and Mail
Dyne Therapeutics (DYN) Keeps 'Outperform' Rating Amid RBC Capital Price Target Cut to $23.00 - AInvest
Dyne Therapeutics Analysts Lower Forecasts Following Q2 Loss - AInvest
Dyne Therapeutics Advances in Neuromuscular Therapies - The Globe and Mail
Dyne Therapeutics Inc. Stock Chart Analysis: Bullish or Bearish Pattern FormingCapital Protection Trading Strategies Gain Interest - metal.it
Dyne Therapeutics Inc. stock prediction for this weekBuy Signal Based on Chart Analysis Confirmed - metal.it
These Analysts Lower Their Forecasts On Dyne Therapeutics Following Q2 Loss - Benzinga
Dyne Therapeutics (DYN) Maintains Rating as RBC Capital Lowers P - GuruFocus
Dyne Therapeutics' Funding to Sustain Operations Through 2027, With Key Milestones Ahead - AInvest
Dyne Therapeutics Advances Clinical Programs and Strengthens Financial Position, with 349.45% Upside Potential - AInvest
Dyne Therapeutics (DYN) Analyst Rating Update: Target Price Lowe - GuruFocus
Can Dyne Deliver And Achieve Milestones In DMD And Myotonic Dystrophy Trials? - RTTNews
Dyne Therapeutics Inc (DYN) 財務データ
収益
当期純利益
現金流量
EPS
0.41%
0.88%
大文字化:
|
ボリューム (24 時間):